Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.
作者信息
Shakeri Ahmad, Hayes Kaleen N, Gomes Tara, Tadrous Mina
机构信息
Women's College Research Institute, Women's College Hospital, Toronto, Ontario, Canada.
Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
出版信息
Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.
Abstract
摘要
相似文献
1
Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.
Can Liver J. 2021 Nov 11;4(4):426-429. doi: 10.3138/canlivj-2020-0041. eCollection 2021 Fall.
2
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
J Int AIDS Soc. 2017 Nov;20(3). doi: 10.1002/jia2.25013.
3
Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
J Hepatol. 2017 Jul;67(1):15-22. doi: 10.1016/j.jhep.2017.01.024. Epub 2017 Feb 9.
4
Assessing the Risk of Decrease in Kidney Function in Patients Prescribed Direct-Acting Antivirals for Hepatitis C Utilizing the MID-NET Medical Information Database Network in Japan.
Ther Innov Regul Sci. 2022 Jul;56(4):625-631. doi: 10.1007/s43441-022-00400-5. Epub 2022 Apr 18.
5
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
6
Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment.
Liver Int. 2021 Mar;41(3):464-469. doi: 10.1111/liv.14761. Epub 2020 Dec 23.
7
Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan.
Braz J Biol. 2021 Dec 13;83:e252610. doi: 10.1590/1519-6984.252610. eCollection 2021.
8
A real-world observational study of drug utilization and clinical outcomes of direct-acting antivirals and interferon therapy for hepatitis C treatment in Taiwan.
Curr Med Res Opin. 2021 Feb;37(2):245-252. doi: 10.1080/03007995.2020.1857716. Epub 2021 Jan 13.
9
Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
J Viral Hepat. 2017 Aug;24(8):624-630. doi: 10.1111/jvh.12684. Epub 2017 Feb 20.
10
Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
HIV Med. 2018 Mar;19(3):216-226. doi: 10.1111/hiv.12570. Epub 2017 Dec 1.
引用本文的文献
1
Universal Pharmacare and Contraceptive Dispensations Among Youth.
JAMA Pediatr. 2025 Aug 18. doi: 10.1001/jamapediatrics.2025.2585.
2
Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.
J Subst Use Addict Treat. 2024 Dec;167:209524. doi: 10.1016/j.josat.2024.209524. Epub 2024 Sep 26.
3
The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
PLoS One. 2023 Aug 8;18(8):e0284914. doi: 10.1371/journal.pone.0284914. eCollection 2023.
4
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.
Can Liver J. 2023 Jul 26;6(2):190-200. doi: 10.3138/canlivj-2022-0040. eCollection 2023 Jul.
5
Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.
Int J Equity Health. 2023 Jun 6;22(1):112. doi: 10.1186/s12939-023-01924-4.
6
Regional differences in access to direct-acting antiviral treatments for hepatitis C across Ontario: A cross-sectional study.
Can Commun Dis Rep. 2022 Apr 6;48(4):179-180. doi: 10.14745/ccdr.v48i04a08.
本文引用的文献
1
Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018.
Value Health. 2020 Sep;23(9):1137-1141. doi: 10.1016/j.jval.2020.03.021. Epub 2020 Jul 28.
2
Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3.
3
National trends in prescription drug expenditures and projections for 2020.
Am J Health Syst Pharm. 2020 Jul 23;77(15):1213-1230. doi: 10.1093/ajhp/zxaa116.
4
Direct-acting antiviral treatment for hepatitis C.
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
5
Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015.
Can J Diabetes. 2019 Apr;43(3):179-185.e1. doi: 10.1016/j.jcjd.2018.08.190. Epub 2018 Aug 16.
6
Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.
J Pharm Policy Pract. 2018 Nov 7;11:28. doi: 10.1186/s40545-018-0154-x. eCollection 2018.
7
Moving towards Universal Coverage of Direct-Acting Antiviral Therapies for Hepatitis C Infection in Canada: An Environmental Scan of Canadian Provinces and International Jurisdictions.
J Pharm Pharm Sci. 2018;21(1s):271s-308s. doi: 10.18433/jpps30220.
8
Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults.
Can Geriatr J. 2018 Sep 30;21(3):269-273. doi: 10.5770/cgj.21.307. eCollection 2018 Sep.
9
Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.
Can Commun Dis Rep. 2014 Dec 18;40(19):429-436. doi: 10.14745/ccdr.v40i19a02.
10
Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program.
CMAJ Open. 2018 Mar 14;6(1):E132-E138. doi: 10.9778/cmajo.20170132.
Zotero 插件